iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
IBIO, Inc. (NASDAQ: IBIO) Delayed: 1.74 +0.05 (2.96%)
Previous Close $1.69    52 Week High $0.80 
Open $1.70    52 Week Low $0.34 
Day High $1.76    P/E N/A 
Day Low $1.68    EPS $-0.08 
Volume 904,455